Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)

NCT03504488 is registered in ClinicalTrials.gov with BioAtla, Inc. as lead sponsor.

NCT NCT03504488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03504488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
Lead sponsor
BioAtla, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 27, 2018
Completion date
December 30, 2024
Enrollment
132 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, melanoma, non small cell lung cancer, triple negative breast cancer